Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield

Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)

July 31, 2017 9:12 AM EDT

Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP).The sBLA is based on a Phase 3 study evaluating the safety and efficacy of Prolia... More

Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980

July 31, 2017 9:03 AM EDT

Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin® (trastuzumab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA... More

AbbVie to remain cautious on drug pricing, shares fall

July 28, 2017 7:54 AM EDT

By Manas Mishra and Natalie Grover

(Reuters) - AbbVie Inc's (NYSE: ABBV) said it would be cautious with drug pricing, especially for Humira, the world's biggest selling drug, sending its shares down 2 percent, despite the drugmaker's quarterly profit narrowly beating estimates.

Abbvie CEO Richard Gonzalez said on Friday the company would continue to be "careful and conservative" about pricing, even though the drugmaker has already concluded negotiations with insurers for coverage of its Humira drug in 2017 and 2018.

"I'd say even in this last cycle, we have been even a... More

Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events

July 27, 2017 5:51 PM EDT

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Amgen's supplemental Biologics License Application (sBLA) for Repatha® (evolocumab), a PCSK9 inhibitor. If approved by the FDA, the U.S. Prescribing Information for Repatha will be updated to include risk reduction of major... More

Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'

July 27, 2017 10:11 AM EDT

Argus raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Buy rating, following the company's second quarter earnings report.

Analyst David Toung notes the company delivered second quarter earnings per share and revenue results above consensus projections fueled by several... More

Amgen (AMGN) PT Raised to $180 at UBS Following Solid 2Q

July 26, 2017 8:34 AM EDT

UBS raised its price target on Amgen (NASDAQ: AMGN) to $180.00 (from $175.00) while maintaining a Neutral rating. 2Q results were better than expectations with a $145M top-line beat. EPS also beat consensus estimates by $0.18.

UBS increased 2017 Enbrel sales estimates to $5.38B from $5B... More

Amgen (AMGN): Strong Q2 2017; Raising Target Price - Oppenheimer

July 26, 2017 6:23 AM EDT

Oppenheimer analyst, Leah Rush Cann, reiterated her Outperform rating on shares of Amgen (NASDAQ: AMGN) and raised her price target to $203 after earnings beat expectations due to higher than estimated product sales and a lower than estimated tax rate. Revenue upside was primarily... More

Amgen (AMGN) PT Raised to $174 at Deutsche Bank

July 26, 2017 6:18 AM EDT

Deutsche Bank raised its price target on Amgen (NASDAQ: AMGN) to $174.00 (from $172.00) while maintaining a Hold rating.

Analyst Andrew Peters called the quarter "solid" but said the near term outlook remains challenged.

"While the results beat expectations, we remain cautious on... More

BMO Capital Downgrades Amgen (AMGN) to Market Perform

July 26, 2017 5:09 AM EDT

BMO Capital downgraded Amgen (NASDAQ: AMGN) from Outperform to Market Perform with a price target of $199.00.

Analyst Ian Somaiya called the Q2 beat "poor-quality" and says catalysts in the NT are lacking. Valuation has caught up to Somaiys'a fundamental outlook according to a... More